Post-transplant EBV induced lymphoproliferative disorders

Leukemia and Lymphoma

Volumn 25, Issue 1-2, 1997, Pages 1-8

  Lucas, Kenneth G ^a,b   Pollok, Karen E ^a   Emanuel, David J ^a  

^a INDIANA UNIVERSITY   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

Lymphoproliferative disorders; Post transplant EBV induced lymphomas

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; BONE MARROW TRANSPLANTATION; CELLULAR IMMUNITY; EPSTEIN BARR VIRUS; HERPES VIRUS INFECTION; HUMAN; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW;

EID: 0030951471     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709042491     Document Type: Review

References (68)

1. Joncas, J. H., Russo, P., Brochu, P., et al. (1990). Epstein-Barr virus polymorphic B-cell lymphoma associated with leukemia and with congenital immunodeficiencies. J. Clin. Oncol., 8, 378.
2. Saemundsen, A. K., Berkel, A. I., Henle, W., et al. (1981). Epstein-Barr virus carrying lymphoma in a patient with ataxia telangiectasia. Br. Med. J., 282, 425.
3. Purtilo, D. T., Yang, J. P. S., Cassel, C. K., et al. (1975). X-linked recessive progressive combined variable imunodeficiency (Duncan's disease). Lancet, 1, 935.
4. Shapiro, R. S., McClain, K., Frizzera, G., et al. (1988). Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood, 71, 1234.
5. Zutter, M. M., Martin, P. J., Sale, G. E., et al. (1988). Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood, 72, 520.
6. Martin, P. J., Shulman, H. M., Scubach, W. H., et al. (1984) Fatal Epstein-Barr virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann. Intern. Med., 101, 310.
7. Weintraub, J. and Warnke, R. A. (1982). Lymphoma in cardiac allograft recipients. Clinical and histological features and immunological phenotype. Transplantation, 33, 347.
8. Randhawa, P. S., Yousem, S A., Paradis, I. L., et al. (1989). The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus associated lymphoproliferative disorders in heart-lung transplant recipients. Am. J. Clin. Pathol., 92, 177.
9. Wilkinson, A. H., Smith, J. L., Hunsicker, L. G., et al. (1989). Increased frequency of post transplant lymphomas in patients treated with cyclosporin, azathioprine, and prednisone. Transplantation, 47, 293.
10. Shibata, D., Weiss, L. M., Nathwani, B. N., Brynes, R. K. and Levine, A. M. (1991). Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma. Blood, 77, 1527.
11. Roithman, S., Toledano, M., Tourani, J. M., et al. (1991). HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French registry of HIV-associated tumors. Ann. Oncol., 2, 289.
12. Carbone, A., Tirelli, U., Gloghini, A., Volpe, R. and Boiocchi, M. (1993). Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J. Clin. Oncol., 11, 1674.
13. Lucas, K. G., Small, T. N., Heller, G., Dupont, B. and O'Reilly, R. J. (1996). The development of cellular immuity to Epstein-Barr virus following allogeneic bone marrow transplantation. Blood, 87, 2594.
14. Swinnen, L. J., Costanzo-Nordin, M. R., Fisher, S. G., et al. (1990). Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N. Engl. J. Med., 323, 1723.
15. Renard, T. H., Andrews, W. S and Foster, M. E. (1991). Relationship between OKT3 administration. EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant patients. Transplant Proc., 23, 1473.
16. Starzl, T. E., Porter, K. A. and Iwatsuki, S. (1984). Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet, 1, 583.
17. Tosato, G. (1987). The Epstein-Barr virus and the immune system. Adv. Cancer Res., 49, 75.
18. Jigl, W., Sieger, E., Alliger, P. and Wolf, H. (1989). Identification of type A and B isolates of Epstein-Barr virus by polymerase chain reaction. J. Virol Methods, 30, 319.
19. Rowe, M., Young, L. S., Crocker, J., Stokes, H., Henderson, S. and Rickinson, A. B. (1991). Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J. Exp. Med., 173, 147.
20. Levitskaya, J., Coram, M., Levitsky, V., et al. (1995). Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature, 375, 685.
21. Teo, C. G. and Griffin, B. E. (1987). Epstein-Barr virus genomes in lymphoid cells' activation in mitosis and chromosomal translocation. Proc. Natl. Acad. Sci. USA, 84, 8473.
22. Purtilo, D. T., Strobach, R S., Okano, M. and Davis, J. R. (1992). Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest., 67, 5.
23. Hudson, G. S., Bankier, A. T., Satchwell, S. C. and Barrell, B. G. (1985). The short unique region of the B95-8 Epstein-Barr virus genome. Virol., 147, 81.
24. Henderson, S., Rowe, M., Gregory, C.,et al. (1991). Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 65, 1107.
25. Okano, M., Thiele, G. M., Davis, J. R., Grierson, H. L. and Purtilo, D. T. (1988). Epstein-Barr virus and human diseases: recent advances in diagnosis Clin. Microbiol. Rev., 1, 300.
26. Tomkinson, B. E., Maziarz, R. and Sullivan, J. L. (1989). Characterization of the T-cell mediated cellular cytotoxicity during acute infectious mononucleosis. J. Immunol., 143, 660.
27. Lotz, M., Tsoukas, C. D., Fong, S., Dinarello, C. A., Carson, D. A. and Vaughan, J. H. (1986). Release of lymphokines after Epstein-Barr virus infection in vitro. I. Source of and kinetics of production of interferons and interleukin in normal human. J. Immunol., 136, 3636.
28. Rickinson, A. B., Moss, D. J., Wallace, L. E., et al. (1981). Long-term T-cell-mediated immunity to Epstein-Barr virus. Cancer Res, 41, 4216.
29. Wallace, L., Rowe, M., Rickinson, A. B. and Epstein, M. A. (1982). Cytotoxic T recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2. Eur. J. Immunol., 12, 1012.
30. Chen, B. P., Lam, V., Kraus, E. E., DeMars, R. and Sondel, P. M. (1989). Restriction of Epstein-Barr virus-specific cytotoxic T cells by HLA-A, -B, and -C molecules. Human Immunology, 26, 137.
31. Strang, G. and Rickinson, A. B. (1987). Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis. Eur. J. Immunol., 17, 1007.
32. Klein, E., Ernberg, I., Mascucci, M. G., et al. (1981). T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis. Cancer Res., 41, 4210.
33. Misko, I. S., Moss, D. J. and Pope, J. H. (1980). HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc. Natl. Acad Sci., 77, 4247.
34. Murray, R. J., Kurilla, M. G., et al. (1992). Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med., 176, 157.
35. Keever, C. A., Welte, K., Small, T., et al. (1987). Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow. Blood, 70, 1893.
36. Welte, K., Keever, C. A., Levick, J., Bonilla, M A., Merluzzi, V. J. and Mertelsmann, R. (1987). Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T-cell depleted bone marrow. Blood, 70, 1595.
37. Torsteindottir, S., Mascucci, M. G., Szigeti, R., Bishara, A., Brautbar, C. and Klein, E (1984). T lymphocyte culture established by repeated stimulation with the autologous lymphoblastoid line. Mol. Biol. Med., 2, 285.
38. Misko, I. S., Pope, J. H., Soszynski, T. D., Kane and R. G (1984). HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int. J Cancer, 33, 239.
39. Keever, C A., Small, T. N., Flomenberg, N., et al. (1989). Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood, 73, 1340.
40. Ault, K. A., Antin, J. H., Ginsburg, D., et al. (1985). Phenotype of recovering lymphoid cell populations after marrow transplantation. J. Exp. Med., 161, 1483.
41. Rickinson, A. B., Young, L. S. and Rowe, M. (1987). Influence of the Epstein-Barr virus nuclear antigen EBNA-2 on the growth phenotype of virus-transformed B cells. J. Virol., 61, 1310.
42. Frank, D., Cesarman, E., Lieu, Y. U., et al. (1995). Post transplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood, 85, 1396.
43. Savoie, A. Perpete, C., Carpentier, L., et al. (1994) Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease Blood, 83, 2715.
44. Swerdlow, S. H. (1992). Post-transplant lymphoproliferative disorders: A morphologic, phenotypic and genotypic spectrum of disease. Histopathol., 20, 373.
45. Hjelle, B., Evans-Holm, M., Yents, Garovoy, M., Guim and Edman, S. C. (1989). A poorly differentiated lymphoma of donor origin in a renal allograft recipient. Transplant. 47, 945.
46. Nalesnik, M A., Jaffe, R., Starzl, T. E., et al. (1988). The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am. J. Pathol., 133, 173.
47. Armitage, J. M., Kormos, R. L., et al. (1991). Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J. Heart Lung Transplant, 10, 877.
48. Ho, M., Jaffe, R., Miller, G., et al. (1988). The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children Transplant, 45, 719.
49. Bieber, C. P., Heberling, R. L., Jamieson, S W., et al (1984). Lymphoma in cardiac transplant recipients associated with cyclosporine, prednisone and anti-thymocyte globulin (ATG). in Purtilo DT (ed): Immune deficiency and cancer. New York. NY, Plenum, 309.
50. Malatack, J. J., Gartner, J C., Urbach, A. H. and Zitelli, B. J. (1991). Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: A growing concern. J Ped., 118, 667.
51. Penn, I. and First, M. R (1986). Development and incidence of cancer following cyclosporine therapy. Transplant Proc., 18, 210.
52. Crompton, C. H., Cheung, R K., Donjon, C., et al. (1994). Epstein-Barr virus surveillance after renal transplantation. Transplantation, 57, 1182.
53. Penn, I. (1987). Cancers following cyclosporine therapy. Transplant Proc., 19, 2211.
54. Olivari, M. T., Dieckmann, R. A., Kubo, S. H., Braunlin, E., Jamieson, S. W. and Ring, S (1990). Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression J Heart Transplant, 9, 618.
55. Nalesnik, M. A., Makowa, L. and Starzl, T. E. (1988). The diagnosis and treatment of posttransplant lymphoproliferative disorders, in Ravitch M. M., Steichen, F M. (eds): Current problems in surgery, vol xxv, Chicago, IL, Year Book Medical.
56. Frizzera, G., Hanto, D. W., Gail-Peczalska, K. J., et al. (1981). Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res., 41, 4262.
57. Knowles, D. M., Cesarman, E., et al. (1995). Correlative morphology and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders Blood, 85, 552.
58. Thomas, J. A., Hotchin, N. A., Allday, M. J., et al. (1990). Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplant, 49, 944.
59. Riddler, S. A., Breinig, M. C and McKnight, J. K. (1994). Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood, 84, 972.
60. Weiss, L. M. and Movahed, L. A (1989) In situ demonstration of Epstein-Barr viral genomes in viral-associated B cell lymphoproliferations Am. J. Pathol., 134, 651.
61. Seiden, M. V and Sklar, J. (1993). Molecular genetic analysis of post-transplant lymphoproliferative disorders. Hematology/ Oncology Clinics of North America, 7, 447.
62. Rooney, C. M., Smith, C. A., Ng, C. Y., et al (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet, 345, 9.
63. Fischer, A., Blanche, S., LeBidois. J., et al. (1991). Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N. Engl. J. Med., 324, 1451.
64. Papadopoulos, E. B., Ladanyi, M . Emanuel, D., et al. (1994) Infusions of donor leukocytes as treatment of Epstein-Barr virus associated lymphoproliferative disorders complicating allogeneic marrow transplantation. N. Engl. J. Med., 330, 1185.
65. Sullivan, J. L., Medvecsky, P., Forman, S. J., Baker, S. M., Monroe, J. E. and Mulder, C (1984). Epstein-Barr virus induced lymphoproliferation. Implications for anti-viral therapy. N. Eng. J. Med., 311, 1163.
66. Hanto, D W., Frizzera, G., Gajl-Peczalska, K. J., Balfour, H. H. Jr. Simmons, R. L. and Najarian, J. S. (1985). Acyclovir therapy of Epstein-Barr virus-induced post-transplant lymphoproliferative diseases. Transplant Proc., 17, 89.
67. Blanche, S., Ledeist. F., Veber, F., et al. (1988). Treatment of severe Epstein-Barr virus-induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies. Two cases after HLA-mismatched bone marrow transplantation. Ann Intern. Med., 108, 199.
68. Swinnen, L. J., Mullen, G. M., Carr, T. J., Costanzo, M. K. and Fisher, R. I. (1995) Aggressive treatment for postcardiac transplant lymphoproliferation. Blood, 86, 3333.